143 related articles for article (PubMed ID: 2153234)
1. Influence of peptide acylation, liposome incorporation, and synthetic immunomodulators on the immunogenicity of a 1-23 peptide of glycoprotein D of herpes simplex virus: implications for subunit vaccines.
Brynestad K; Babbit B; Huang L; Rouse BT
J Virol; 1990 Feb; 64(2):680-5. PubMed ID: 2153234
[TBL] [Abstract][Full Text] [Related]
2. The influence of different adjuvants on the immune response to a synthetic peptide comprising amino acid residues 9-21 of herpes simplex virus type 1 glycoprotein D.
Geerligs HJ; Weijer WJ; Welling GW; Welling-Wester S
J Immunol Methods; 1989 Nov; 124(1):95-102. PubMed ID: 2553820
[TBL] [Abstract][Full Text] [Related]
3. Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation.
Babu JS; Nair S; Kanda P; Rouse BT
Vaccine; 1995 Dec; 13(17):1669-76. PubMed ID: 8719518
[TBL] [Abstract][Full Text] [Related]
4. Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.
Weijer WJ; Drijfhout JW; Geerligs HJ; Bloemhoff W; Feijlbrief M; Bos CA; Hoogerhout P; Kerling KE; Popken-Boer T; Slopsema K
J Virol; 1988 Feb; 62(2):501-10. PubMed ID: 2826811
[TBL] [Abstract][Full Text] [Related]
5. In vivo induction of anti-herpes simplex virus immune response by type 1 antigens and lipid A incorporated into liposomes.
Naylor PT; Larsen HS; Huang L; Rouse BT
Infect Immun; 1982 Jun; 36(3):1209-16. PubMed ID: 6284643
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.
Hazama M; Mayumi-Aono A; Asakawa N; Kuroda S; Hinuma S; Fujisawa Y
Vaccine; 1993; 11(6):629-36. PubMed ID: 8391739
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
J Virol; 2017 May; 91(9):. PubMed ID: 28228587
[TBL] [Abstract][Full Text] [Related]
8. Development of a herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use.
Burke RL
Rev Infect Dis; 1991; 13 Suppl 11():S906-11. PubMed ID: 1664126
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of adjuvants on efficacy of virion envelope herpes simplex virus vaccine against labial infection of BALB/c mice.
Thomson TA; Hilfenhaus J; Moser H; Morahan PS
Infect Immun; 1983 Aug; 41(2):556-62. PubMed ID: 6307874
[TBL] [Abstract][Full Text] [Related]
10. Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models.
Mishkin EM; Fahey JR; Kino Y; Klein RJ; Abramovitz AS; Mento SJ
Vaccine; 1991 Mar; 9(3):147-53. PubMed ID: 1645898
[TBL] [Abstract][Full Text] [Related]
11. Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8
Lopes PP; Todorov G; Pham TT; Nesburn AB; Bahraoui E; BenMohamed L
J Virol; 2018 Apr; 92(8):. PubMed ID: 29437976
[TBL] [Abstract][Full Text] [Related]
12. Humoral and cellular immune responses to an envelope-associated antigen of herpes simplex virus.
Zaia JA; Palmer EL; Feorino PM
J Infect Dis; 1975 Dec; 132(6):660-6. PubMed ID: 172562
[TBL] [Abstract][Full Text] [Related]
13. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine.
Burke RL; Goldbeck C; Ng P; Stanberry L; Ott G; Van Nest G
J Infect Dis; 1994 Nov; 170(5):1110-9. PubMed ID: 7963702
[TBL] [Abstract][Full Text] [Related]
14. A novel strategy for converting recombinant viral protein into high immunogenic antigen.
Hinuma S; Hazama M; Mayumi A; Fujisawa Y
FEBS Lett; 1991 Aug; 288(1-2):138-42. PubMed ID: 1652468
[TBL] [Abstract][Full Text] [Related]
15. The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine.
Sanchez-Pescador L; Burke RL; Ott G; Van Nest G
J Immunol; 1988 Sep; 141(5):1720-7. PubMed ID: 2842401
[TBL] [Abstract][Full Text] [Related]
16. Interactions of target-sensitive immunoliposomes with herpes simplex virus. The foundation of a sensitive immunoliposome assay for the virus.
Ho RJ; Rouse BT; Huang L
J Biol Chem; 1987 Oct; 262(29):13979-84. PubMed ID: 2820988
[TBL] [Abstract][Full Text] [Related]
17. Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine.
Straus SE; Savarese B; Tigges M; Freifeld AG; Krause PR; Margolis DM; Meier JL; Paar DP; Adair SF; Dina D
J Infect Dis; 1993 May; 167(5):1045-52. PubMed ID: 8387560
[TBL] [Abstract][Full Text] [Related]
18. Functional T cell recognition of synthetic peptides corresponding to continuous antibody epitopes of herpes simplex virus type 1 glycoprotein D.
Wyckoff JH; Osmand AP; Eisenberg RJ; Cohen GH; Rouse BT
Immunobiology; 1988 May; 177(2):134-48. PubMed ID: 2456985
[TBL] [Abstract][Full Text] [Related]
19. Enhanced Immunogenicity and Protective Efficacy of a
Ramakrishnan A; Schumack NM; Gariepy CL; Eggleston H; Nunez G; Espinoza N; Nieto M; Castillo R; Rojas J; McCoy AJ; Beck Z; Matyas GR; Alving CR; Guerry P; Poly F; Laird RM
mSphere; 2019 May; 4(3):. PubMed ID: 31043512
[No Abstract] [Full Text] [Related]
20. Reactivity of human sera with overlapping synthetic peptides of herpes simplex virus type 1 glycoprotein D.
Geerligs HJ; Feijlbrief M; Bolk M; Bos CA; Drijfhout JW; Welling GW; Welling-Wester S
Arch Virol; 1990; 114(3-4):251-8. PubMed ID: 2173527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
